Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Garcia

Showing results (241-250 of 455) with videos related to

Pageof 46
Sort By:
Cell Reports|December 5, 2023
Titin domains with reduced core hydrophobicity cause dilated cardiomyopathyInes Martinez-Martin, Audrey Crousilles, Juan Pablo Ochoa, et al.
JACC. Cardiooncology|April 22, 2026
Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art ReviewJoban Vaishnav, Dimitrios Bampatsias, Brian C Boursiquot, et al.
Heart (British Cardiac Society)|November 1, 2016
Predictors of atrial fibrillation in hypertrophic cardiomyopathyOliver P Guttmann, Menelaos Pavlou, Constantinos O'Mahony, et al.
BMC Pregnancy and Childbirth|January 23, 2021
Gestation and COVID-19: clinical and microbiological observational study (Gesta-COVID19)Anna Suy, Itziar Garcia-Ruiz, Melchor Carbonell, et al.
European Journal of Heart Failure|July 18, 2015
Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)Oliver P Guttmann, Menelaos Pavlou, Constantinos O'Mahony, et al.
JACC. Cardiooncology|June 17, 2026
Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin AmyloidosisDaniel P Judge, Alan X Ji, Isabella A Graef, et al.
JACC. Cardiooncology|November 3, 2021
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes SurveyJose Nativi-Nicolau, Alfonso Siu, Angela Dispenzieri, et al.
Journal of Cardiovascular Translational Research|January 21, 2021
Screening of Fabry Disease in Patients with Chest Pain Without Obstructive Coronary Artery DiseaseAitor Hernández-Hernández, Carles Diez-López, Olga Azevedo, et al.
European Heart Journal|July 31, 2015
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fractionEsther González-López, Maria Gallego-Delgado, Gonzalo Guzzo-Merello, et al.
European Heart Journal|October 7, 2025
Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure AssociationPablo Garcia-Pavia, Esther Gonzalez-Lopez, Lisa J Anderson, et al.
Pageof 46

Showing results (241-250 of 455) with videos related to

Sort By:
Pageof 46
Cell Reports|December 5, 2023
Titin domains with reduced core hydrophobicity cause dilated cardiomyopathyInes Martinez-Martin, Audrey Crousilles, Juan Pablo Ochoa, et al.
JACC. Cardiooncology|April 22, 2026
Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art ReviewJoban Vaishnav, Dimitrios Bampatsias, Brian C Boursiquot, et al.
Heart (British Cardiac Society)|November 1, 2016
Predictors of atrial fibrillation in hypertrophic cardiomyopathyOliver P Guttmann, Menelaos Pavlou, Constantinos O'Mahony, et al.
BMC Pregnancy and Childbirth|January 23, 2021
Gestation and COVID-19: clinical and microbiological observational study (Gesta-COVID19)Anna Suy, Itziar Garcia-Ruiz, Melchor Carbonell, et al.
European Journal of Heart Failure|July 18, 2015
Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)Oliver P Guttmann, Menelaos Pavlou, Constantinos O'Mahony, et al.
JACC. Cardiooncology|June 17, 2026
Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin AmyloidosisDaniel P Judge, Alan X Ji, Isabella A Graef, et al.
JACC. Cardiooncology|November 3, 2021
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes SurveyJose Nativi-Nicolau, Alfonso Siu, Angela Dispenzieri, et al.
Journal of Cardiovascular Translational Research|January 21, 2021
Screening of Fabry Disease in Patients with Chest Pain Without Obstructive Coronary Artery DiseaseAitor Hernández-Hernández, Carles Diez-López, Olga Azevedo, et al.
European Heart Journal|July 31, 2015
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fractionEsther González-López, Maria Gallego-Delgado, Gonzalo Guzzo-Merello, et al.
European Heart Journal|October 7, 2025
Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure AssociationPablo Garcia-Pavia, Esther Gonzalez-Lopez, Lisa J Anderson, et al.
Pageof 46